You are here

Approvals, Launches, and New Indications

Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy
Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Over Half of Patients Had Reduced Pain Levels of 30% or More
Over 25% of Study Patients Showed 6–12 Months Remission
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
Nexus Has Increased Power, RF Capabilities
New Indication for Ceftolozane/Tazobactam Injection
FDA Approves Combination Treatment for Relapsed/Refractory NHL
Rare SMA is Leading Genetic Cause of Infant Mortality
Data Show Drug Significantly Prolongs Survival
Only FDA-Approved Therapy for GVHD in Adults and Children
First Devices Cleared for Diagnostic Testing Via Throat, Rectum Specimens
First New Medication for Seizure Clusters in More Than Two Decades
Averts Disease Worsening, Reduces Potential for Blindness
FDA Removes Boxed Warning With Drug’s Fifth Approval
Kadcyla Cut Risk of Recurring Disease by Half Compared to Herceptin
First Medicines for Adults With Wild-type or Hereditary ATTR-CM
Rare Disorder Typically Co-occurs With Cancer
Global Incidence of Mosquito-Borne Disease Has Increased
Mavyret Now Approved for Adults and Children Over 12
Study Safety Data Support Early Treatment of Underlying Cause of CF
Phase 3 Study Confirmed Drug’s Comparable Safety and Efficacy
Minimally Invasive Method Reduces Regurgitation and Leaking
Medical Device Enables Nerve Stimulation During Sleep
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
More Than 32% of Patients Responded in Trial
Evenity Increases New Bone Formation, Lowers Vertebral Fracture Potential
Dovato Achieved Non-inferior Efficacy Compared to Traditional Regimen; No Cases of Resistance
LAMA/LABA Population Expected to Grow Rapidly in Coming Years